The efficacy and safety of regorafenib/fruquintinib combined with PD-1/PD-L1 for metastatic colorectal cancer: a meta-analysis based on single-arm studies

The efficacy and safety of regorafenib/fruquintinib combined with PD-1/PD-L1 for metastatic colorectal cancer: a meta-analysis based on single-arm studies

ObjectiveThe efficacy of regorafenib or fruquintinib in combination with PD-1/PD-L1 inhibitors for metastatic colorectal cancer (mCRC) treatment has not been elucidated. This study aims to systematically evaluate the efficacy and safety of this combination therapy.MethodsPubMed, Embase, Cochrane Lib...

Full description

Saved in:
Bibliographic Details
Main Authors: Fan Yang, Ying Mao, Hanyu Huang, Wen Luo, Li Liu, Wenzhi Chen
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-05-01
Series:Frontiers in Immunology
Subjects:
metastatic colorectal cancer
regorafenib
fruquintinib
PD-1/PD-L1 inhibitors
meta-analysis
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2025.1579293/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items